BR112018074972A2 - derivados de adenosina para uso no tratamento de câncer - Google Patents

derivados de adenosina para uso no tratamento de câncer

Info

Publication number
BR112018074972A2
BR112018074972A2 BR112018074972-9A BR112018074972A BR112018074972A2 BR 112018074972 A2 BR112018074972 A2 BR 112018074972A2 BR 112018074972 A BR112018074972 A BR 112018074972A BR 112018074972 A2 BR112018074972 A2 BR 112018074972A2
Authority
BR
Brazil
Prior art keywords
cancer treatment
adenosine derivatives
adenosine
derivatives
cancer
Prior art date
Application number
BR112018074972-9A
Other languages
English (en)
Inventor
Griffith Hugh
Serpi Michaela
Slusarczyk Magdalena
Mcguigan Christopher
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NuCana plc filed Critical NuCana plc
Publication of BR112018074972A2 publication Critical patent/BR112018074972A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção se refere a compostos químicos de fórmula (i) conforme definida nas reivindicações, sua preparação e seu uso no tratamento de câncer.
BR112018074972-9A 2016-06-01 2017-05-31 derivados de adenosina para uso no tratamento de câncer BR112018074972A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1609602.6A GB201609602D0 (en) 2016-06-01 2016-06-01 Chemical compounds
GB1609602.6 2016-06-01
PCT/GB2017/051554 WO2017207989A1 (en) 2016-06-01 2017-05-31 Adenosine derivatives for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
BR112018074972A2 true BR112018074972A2 (pt) 2019-03-12

Family

ID=56410851

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018074972-9A BR112018074972A2 (pt) 2016-06-01 2017-05-31 derivados de adenosina para uso no tratamento de câncer

Country Status (17)

Country Link
US (1) US20190375778A1 (pt)
EP (1) EP3464308B1 (pt)
JP (1) JP2019520345A (pt)
KR (1) KR20190015355A (pt)
CN (1) CN109563122A (pt)
AU (1) AU2017273120A1 (pt)
BR (1) BR112018074972A2 (pt)
CA (1) CA3025435A1 (pt)
CL (1) CL2018003444A1 (pt)
EA (1) EA201892802A1 (pt)
GB (1) GB201609602D0 (pt)
IL (1) IL263120A (pt)
MX (1) MX2018014849A (pt)
PH (1) PH12018502497A1 (pt)
SG (1) SG11201810146SA (pt)
WO (1) WO2017207989A1 (pt)
ZA (1) ZA201807810B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
US10570168B2 (en) 2014-11-28 2020-02-25 NuCana plc 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compounds
HUE049918T2 (hu) 2016-05-31 2020-11-30 Kalvista Pharmaceuticals Ltd Pirazol-származékok mint plazma kallikrein inhibitorok
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201709471D0 (en) * 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
IL274557B1 (en) 2017-11-29 2024-05-01 Kalvista Pharmaceuticals Ltd Dosage forms containing a plasma kallikrein inhibitor
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
GB201820685D0 (en) 2018-12-19 2019-01-30 NuCana plc Synthesis of 8-chloroadenosine derivatives
CN114206852A (zh) 2019-08-09 2022-03-18 卡尔维斯塔制药有限公司 血浆激肽释放酶抑制剂
CN113549076B (zh) * 2021-07-23 2022-12-06 中国药科大学 一种多取代嘌呤类化合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
JP2016506371A (ja) * 2012-11-16 2016-03-03 ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド ヌクレオシドプロドラッグを調製する方法
CN103435672A (zh) * 2013-04-25 2013-12-11 刘沛 含有取代苄基的新型核苷磷酸酯前药的结构与合成
BR112016011949A8 (pt) * 2013-11-27 2020-04-28 Idenix Pharmaceuticals Llc composto, composição farmacêutica, e, uso dos mesmos”

Also Published As

Publication number Publication date
IL263120A (en) 2018-12-31
US20190375778A1 (en) 2019-12-12
CL2018003444A1 (es) 2019-05-10
CN109563122A (zh) 2019-04-02
EA201892802A1 (ru) 2019-06-28
WO2017207989A1 (en) 2017-12-07
PH12018502497A1 (en) 2019-04-08
ZA201807810B (en) 2021-04-28
GB201609602D0 (en) 2016-07-13
SG11201810146SA (en) 2018-12-28
JP2019520345A (ja) 2019-07-18
EP3464308B1 (en) 2020-08-19
EP3464308A1 (en) 2019-04-10
AU2017273120A1 (en) 2018-12-06
CA3025435A1 (en) 2017-12-07
KR20190015355A (ko) 2019-02-13
MX2018014849A (es) 2019-03-14

Similar Documents

Publication Publication Date Title
BR112018074972A2 (pt) derivados de adenosina para uso no tratamento de câncer
CY1124726T1 (el) Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
EA201890125A1 (ru) Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
EA201791563A1 (ru) Замещенные нуклеозидные производные, полезные в качестве агентов против рака
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
BR112018075166A2 (pt) derivados de carbonucleosídeo substituídos úteis como agentes anticâncer
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
BR112016023558A2 (pt) compostos úteis como imunomoduladores
EA201692219A1 (ru) Способы получения противовирусных соединений
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
CL2018002811A1 (es) Derivados de aminotiazol útiles como agentes antivíricos.
BR112017012005A2 (pt) compostos orgânicos
BR112018011525A2 (pt) inibidores da tirosina quinase de bruton e métodos de seu uso
PH12015502747A1 (en) Novel compounds for the treatment of cancer
ECSP16096831A (es) Derivados de naftiridinadiona
BR112017016333A2 (pt) compostos anticâncer
NI201500176A (es) Derivados de prodroga de triazolpiridinas sustituidas
BR112017012007A2 (pt) compostos orgânicos
BR112017019816A2 (pt) compostos, composição farmacêutica, método para o tratamento profilático ou terapêutico de doença dos rins e/ou fígado em um sujeito, e uso de um composto
CY1121388T1 (el) Παραγωγα βενζυλυδροξειδιου, παρασκευη αυτων και θεραπευτικη χρηση αυτων
BR112017012317A2 (pt) compostos para o tratamento de câncer.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]